文献速递前列腺癌

分子医学肿瘤委员会:全基因组测序指导晚期前列腺癌个体化治疗

Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-10

本文报告一例84岁白人男性Gleason 10寡转移激素敏感前列腺癌患者,接受肿瘤与胚系全基因组测序并公开基因组与临床数据。测序揭示SPOP突变及雄激素受体依赖,与放疗和激素治疗的持久缓解一致,并将该患者置于PCAWG大队列中比较。分子肿瘤委员会整合肿瘤学与基因组学专长,患者持续缓解。

要点

  • 全基因组测序可揭示晚期前列腺癌的突变过程与SPOP突变。
  • SPOP驱动的前列腺癌对激素治疗敏感,表现为持久缓解。
  • 可识别潜在可操作的基因组病变,为未来治疗提供依据。

核心结论

  • 整合肿瘤学与基因组学专长的分子肿瘤委员会可指导晚期前列腺癌患者的诊疗与研究,该患者对联合模式治疗持续 outstanding 缓解。

研究设计与样本

  • 病例报告:一例84岁白人男性Gleason 10寡转移激素敏感前列腺癌患者,接受肿瘤与胚系全基因组测序,并同意公开基因组与临床数据。
  • 将该患者置于PCAWG(泛癌全基因组分析)大型前列腺癌队列中进行比较。

主要发现

  • 全基因组测序揭示肿瘤的潜在突变过程及SPOP突变的产生。
  • 测序显示癌症的雄激素受体依赖,反映为对放疗和激素治疗的持久缓解。
  • 通过个体化医学方法识别肿瘤中潜在可操作的基因组病变,供未来治疗参考;患者目前仍处于缓解。
  • 与PCAWG队列比较,该患者癌症的体细胞突变数量和类型典型,但与衰老相关的突变过程贡献略大。

临床怎么用

  • 对晚期前列腺癌患者可考虑肿瘤与胚系全基因组测序,以揭示突变过程、SPOP突变及雄激素受体依赖。
  • 全基因组测序可识别潜在可操作的基因组病变,为未来个体化治疗提供依据。
  • 分子肿瘤委员会可整合肿瘤学与基因组学专长,优化患者诊疗与研究。

局限性

  • 为单例病例报告,结论不能推广至所有晚期前列腺癌患者。
  • 患者为可识别个体,但已同意公开基因组与临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Molecular profiling of cancer is increasingly common as part of routine care in oncology, and germline and somatic profiling may provide insights and actionable targets for men with metastatic prostate cancer. However, all reported cases are of deidentified individuals without full medical and genomic data available in the public domain. PATIENT AND METHODS: We present a case of whole-genome tumor and germline sequencing in a patient with advanced prostate cancer, who has agreed to make his genomic and clinical data publicly available. RESULTS: We describe an 84-year-old Caucasian male with a Gleason 10 oligometastastic hormone-sensitive prostate cancer. Whole-genome sequencing provided insights into his tumor's underlying mutational processes and the development of an SPOP mutation. It also revealed an androgen-receptor dependency of his cancer which was reflected in his durable response to radiation and hormonal therapy. Potentially actionable genomic lesions in the tumor were identified through a personalized medicine approach for potential future therapy, but at the moment, he remains in remission, illustrating the hormonal sensitivity of his SPOP-driven prostate cancer. We also placed this patient in the context of a large prostate-cancer cohort from the PCAWG (Pan-cancer Analysis of Whole Genomes) group. In this comparison, the patient's cancer appears typical in terms of the number and type of somatic mutations, but it has a somewhat larger contribution from the mutational process associated with aging. CONCLUSION: We combined the expertise of medical oncology and genomics approaches to develop a molecular tumor board to integrate the care and study of this patient, who continues to have an outstanding response to his combined modality treatment. This identifiable case potentially helps overcome barriers to clinical and genomic data sharing.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Armstrong AJ, Li X, Tucker M, et al. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33568750. doi:10.1038/s41391-021-00324-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。